Canadian Court Won't Shrink Paxil Birth Defect Class

Law360, New York (October 28, 2013, 4:58 PM EDT) -- A Canadian appeals court on Friday rejected GlaxoSmithKline Inc.'s efforts to significantly limit class certification on failure-to-warn issues in a suit claiming the antidepressant Paxil causes birth defects, siding with a 19-year class period over the three-year stretch the company sought.

The Court of Appeal for British Columbia tossed GSK's appeal of a lower court order that certified a class of consumers who were prescribed Paxil between the date it was first sold in 1993 and the December 2012 class certification. The company had sought on appeal to limit certification on the issue of duty to warn to those who used...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!